Shared on15 Oct 25Fair value Increased 1.10%
Analysts have slightly raised their price target for Chugai Pharmaceutical from ¥8,082 to ¥8,171, citing improved outlooks for revenue growth and profit margins. What's in the News Chugai Pharmaceutical and Eli Lilly announced positive Phase 3 results from the ACHIEVE-3 trial, showing orforglipron delivered superior improvements in glycemic control and weight loss for adults with type 2 diabetes compared to oral semaglutide.
Shared on05 Sep 25
Given the lack of material changes in both Chugai Pharmaceutical's revenue growth forecasts and future P/E ratio, analysts have maintained their consensus price target at ¥8,082. What's in the News Orforglipron, an investigational GLP-1 receptor agonist, achieved positive topline results in two Phase 3 trials (ATTAIN-1 and ATTAIN-2), demonstrating significant weight loss, HbA1c reduction, and improvements in cardiometabolic risk factors, with a safety profile consistent with its drug class.
Shared on23 Apr 25Fair value Increased 1.01%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 0.81%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 0.061%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 4.39%
AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 6.33%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.